Samples of recent work
Needs Assessment: Novel Hormone Therapy Combinations for Prostate Cancer
This needs assessment
Excerpt
In 2023 there was a flurry of FDA approvals for treating BRCA1/2-mutated mCRPC with a new first-line therapy: PARP inhibitors combined with NHT. Three new regimens were shown to specifically benefit patients bearing BRCA1/2 and other HRR mutations. Thus, NGS testing is required for the new combinations.
Plain Language Explainer: Understanding a Migraine Medication’s Clinical Trial Results
Venue Name
New York, NY